GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS^©): psychometric properties and clinically meaningful thresholds as assessed in the Phase 3 DeFi randomized controlled clinical trial.

"Declarations Conflict of interestMMG has served on advisory boards for or received personal honoraria and/or associated research paid to institution from SpringWorks Therapeutics, Inc; employer (MSKCC) owns license for GODDESS©; he is a Scientific Director of Desmoid Tumor Research Foundation (uncompensated). TMA MM: Employer (MSKCC) owns license for GODDESS©. CD, PG: Employee of IQVIA. TB, LMS, AL: Employee of and hold equity in SpringWorks Therapeutics, Inc. Conflict of interest MMG has served on advisory boards for or received personal honoraria and/or associated research paid to institution from SpringWorks Therapeutics, Inc; employer (MSKCC) owns license for GODDESS©; he is a Scientific Director of Desmoid Tumor Research Foundation (uncompensated). TMA MM: Employer (MSKCC) owns license for GODDESS©. CD, PG: Employee of IQVIA. TB, LMS, AL: Employee of and hold equity in SpringWorks Therapeutics, Inc."

"Funding This work was supported by SpringWorks Therapeutics, Inc., who sponsored this study and the DeFi clinical trial (NCT03785964). The Sponsor was involved with the study design, interpretation of the data, writing of the study report, and in the decision to submit the manuscript for publication and provided funding for the analysis and manuscript preparation by IQVIA. The development of the GODDESS© tool was funded by the Desmoid Tumor Research Foundation and core facility support by Memorial Sloan Kettering Cancer Center Core Grant P30-CA008748–53."

"Trial registration number and registration date NCT03785964; December 24, 2018."